Funding Opportunities

The University of Colorado Cancer Center is pleased to offer grants to support the development of exceptional research projects leading to the ultimate conquest of cancer and furthering CU Cancer Center objectives. Studies in all areas of cancer research—laboratory, clinical, prevention and control, and psycho-social cancer research—will be considered for funding.     


Additional Funding Opportunities

Congressionally Directed Medical Research Programs

Fiscal Year 2021 (FY21) pre-announcements and funding opportunities for the Department of Defense (DoD) programs managed by the office of Congressionally Directed Medical Research Programs (CDMRP) are below.

  • Kidney Cancer Research Program (KCRP)
  • Academy of Kidney Cancer Investigators – Early Career Investigators Award
  • Clinical Trial Award (NEW for FY21)
  • Clinical Research Nurse Development Award
  • Concept Award
  • Idea Development Award
  • Postdoctoral and Clinical Fellowship
  • Translational Research Partnership Award Prostate Cancer Research Program (PCRP)
  • Data Science Award (NEW for FY21)
  • Health Equity Research and Outcomes
  • Improvement Consortium (HEROIC) Award (NEW for FY21)
  • Early Investigator Research Award
  • Physician Research Award
  • Translational Science Award
  • Health Disparity Research Award
  • Idea Development Award
  • Clinical Consortium Award

For more information on these and other awards visit:

Phi Beta Psi Sorority

We are a non-academic women’s organization whose national project is raising money to fund Cancer Research Grants. Last year we awarded six Cancer Research Grants across the country. We would like to invite your program to submit a Request for Proposal to be considered for a grant from our organization.

Click here for instructions on applying.

Application deadline: June 15, 2021

CU Innovations Bridgebio


CU Innovations is partnering with BridgeBio to develop new treatments for diseases with an underlying genetic basis. We are seeking researchers who have therapeutic technology they would like to advance toward clinical development.

View the call for proposal here.

Deadline for Applications: May 12, 2021



NCI’s Division of Cancer Treatment and Diagnosis (DCTD) is excited to announce the availability of cell therapy and viral vector manufacturing capabilities to support the clinical development of cell-based immunotherapy.


Following our initial efforts to support the production of CAR T-cells for multi-center clinical trials, the NCI Biopharmaceutical Development Program at the Frederick National Laboratory for Cancer Research is now offering viral vector production for the genetic modification step in cell therapy manufacturing.


Investigators in need of clinical grade vector and/or cell therapy product manufacturing can submit project proposals to the NCI Experimental Therapeutics (NExT Program). 


Additional background on NCI’s cell therapy initiative:

NCI Initiative Aims to Boost CAR T-cell Therapy Clinical Trials

NExT: Advancing Promising Cancer Therapies from the Lab to Clinical Trials


For more information, please contact:

Jason Yovandich, PhD

Chief, Biological Resources Branch, Developmental Therapeutics Program, DCTD, NCI 


Next cycle for submission opens May 15, 2021 and closes June 15, 2021.